Pharmacology of systemic antifungal agents

被引:203
作者
Ashley, Elizabeth S. Dodds
Lewis, Russell
Lewis, James S.
Martin, Craig
Andes, David
机构
[1] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27710 USA
[2] Campbell Univ, Sch Pharm, Buies Creek, NC 27506 USA
[3] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77004 USA
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[6] Univ Texas, Coll Pharm, Austin, TX 78712 USA
[7] Univ Kentucky, Coll Pharm, Pharm Practice & Sci Div, Lexington, KY 40506 USA
[8] Univ Wisconsin, Dept Med, Madison, WI 53706 USA
[9] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA
关键词
D O I
10.1086/504492
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Traditionally, many invasive fungal infections were associated with a poor prognosis, because effective therapeutic options were limited. The recent development of new antifungal agents has significantly contributed to the successful treatment of fungal diseases. These drugs offer novel mechanisms of action and expanded spectrums of activity over traditional treatment options. However, with these new agents comes the need for increased awareness of the potential interactions and toxicities associated with these drugs. Therefore, an understanding of the pharmacokinetic and pharmacodynamic properties of the classes of antifungal compounds is vital for the effective management of invasive fungal infections. This review provides a summary of the pharmacologic principles involved in treatment of fungal diseases.
引用
收藏
页码:S28 / S39
页数:12
相关论文
共 128 条
  • [41] Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model
    González, GM
    Tijerina, R
    Najvar, LK
    Bocanegra, R
    Luther, M
    Rinaldi, MG
    Graybill, JR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1854 - 1859
  • [42] GRAYBILL JR, 2004, 44 INT C ANT AG CHEM
  • [43] GROLL A, 1997, 37 INT C ANT AG CHEM
  • [44] Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation
    Groll, AH
    Kolve, H
    Ehlert, K
    Paulussen, M
    Vormoor, J
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (01) : 113 - 114
  • [45] Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits
    Groll, AH
    Mickiene, D
    Petraitis, V
    Petraitiene, R
    Ibrahim, KH
    Piscitelli, SC
    Bekersky, I
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3322 - 3327
  • [46] Groll AH, 1998, ADV PHARMACOL, V44, P343, DOI 10.1016/S1054-3589(08)60129-5
  • [47] Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
    Groll, AH
    Mickiene, D
    Petraitiene, R
    Petraitis, V
    Lyman, CA
    Bacher, JS
    Piscitelli, SC
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) : 2845 - 2855
  • [48] Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
    Hajdu, R
    Thompson, R
    Sundelof, JG
    Pelak, BA
    Bouffard, FA
    Dropinski, JF
    Kropp, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2339 - 2344
  • [49] Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans
    Hariprasad, SM
    Mieler, WF
    Holz, ER
    Gao, H
    Kim, JE
    Chi, JD
    Prince, RA
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (01) : 42 - 47
  • [50] Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction
    Hebert, MF
    Smith, HE
    Marbury, TC
    Swan, SK
    Smith, WB
    Townsend, RW
    Buell, D
    Keirns, J
    Bekersky, I
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (10) : 1145 - 1152